BHVN241220P57500
- 12.00
- 0.000.00%
Biohaven Newsroom
Morgan Stanley Maintains Biohaven(BHVN.US) With Buy Rating, Maintains Target Price $69
BTIG Maintains Biohaven(BHVN.US) With Buy Rating, Maintains Target Price $59
Jefferies Maintains Biohaven(BHVN.US) With Buy Rating, Maintains Target Price $64
Jefferies Sticks to Their Buy Rating for Biohaven Ltd. (BHVN)
A Quick Look at Today's Ratings for Biohaven(BHVN.US), With a Forecast Between $58 to $76
Biohaven Ltd.: Buy Rating Affirmed Amid Promising Drug Prospects and Strategic FDA Engagement
Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), Vigil Neuroscience Inc (VIGL) and Biohaven Ltd. (BHVN)
Promising Potential of Biohaven's Taldefgrobep Alfa in Obesity Treatment and Niche SMA Market Justifies Buy Rating
RBC Capital Maintains Outperform on Biohaven, Lowers Price Target to $58
Biohaven Analyst Ratings
RBC Cuts Price Target on Biohaven to $58 From $66, Maintains Outperform Rating
Morgan Stanley Maintains Biohaven(BHVN.US) With Buy Rating, Maintains Target Price $69
Biohaven Ltd. (BHVN) Receives a Buy From Morgan Stanley
A Quick Look at Today's Ratings for Biohaven(BHVN.US), With a Forecast Between $59 to $76
Biohaven Is Maintained at Outperform by RBC Capital
RBC Capital Maintains Biohaven(BHVN.US) With Buy Rating, Cuts Target Price to $66
BTIG Maintains Biohaven(BHVN.US) With Buy Rating, Maintains Target Price $59
TD Cowen Maintains Biohaven(BHVN.US) With Buy Rating, Raises Target Price to $75
Biohaven Ltd.'s Strategic Advancements and Promising Pipeline Drive Buy Rating
Biohaven Analyst Ratings